Corline Biomedical Future Growth
Future criteria checks 6/6
Corline Biomedical is forecast to grow earnings and revenue by 114.8% and 68.1% per annum respectively. EPS is expected to grow by 115.1% per annum. Return on equity is forecast to be 28.7% in 3 years.
Key information
114.8%
Earnings growth rate
115.1%
EPS growth rate
| Pharmaceuticals earnings growth | 48.3% |
| Revenue growth rate | 68.1% |
| Future return on equity | 28.7% |
| Analyst coverage | Low |
| Last updated | 03 May 2024 |
Recent future growth updates
Recent updates
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 181 | 113 | 91 | 99 | 1 |
| 12/31/2025 | 60 | 20 | 14 | 21 | 1 |
| 12/31/2024 | 36 | -11 | -21 | -14 | 1 |
| 3/31/2024 | 31 | -4 | -3 | 7 | N/A |
| 12/31/2023 | 36 | -2 | -10 | 1 | N/A |
| 9/30/2023 | 37 | -1 | -12 | -2 | N/A |
| 6/30/2023 | 40 | 1 | -12 | 0 | N/A |
| 3/31/2023 | 38 | 4 | -16 | -5 | N/A |
| 12/31/2022 | 33 | 2 | -15 | -6 | N/A |
| 9/30/2022 | 31 | 1 | -14 | -2 | N/A |
| 6/30/2022 | 23 | -3 | -15 | -6 | N/A |
| 3/31/2022 | 19 | -6 | -16 | -6 | N/A |
| 12/31/2021 | 17 | -7 | -14 | -5 | N/A |
| 9/30/2021 | 15 | -6 | -12 | -6 | N/A |
| 6/30/2021 | 13 | -6 | -12 | -7 | N/A |
| 3/31/2021 | 14 | -6 | -12 | -6 | N/A |
| 12/31/2020 | 15 | -7 | -14 | -5 | N/A |
| 9/30/2020 | 14 | -9 | -20 | -7 | N/A |
| 6/30/2020 | 14 | -9 | -20 | -9 | N/A |
| 3/31/2020 | 14 | -9 | -20 | -11 | N/A |
| 12/31/2019 | 12 | -10 | -19 | -14 | N/A |
| 9/30/2019 | 11 | -9 | -17 | -17 | N/A |
| 6/30/2019 | 11 | -9 | -5 | -5 | N/A |
| 3/31/2019 | 10 | -8 | -5 | -4 | N/A |
| 12/31/2018 | 10 | -7 | -5 | -4 | N/A |
| 9/30/2018 | 17 | -7 | -8 | -6 | N/A |
| 6/30/2018 | 16 | -6 | -18 | -15 | N/A |
| 3/31/2018 | 15 | -7 | -19 | -16 | N/A |
| 12/31/2017 | 16 | -8 | N/A | -5 | N/A |
| 9/30/2017 | 7 | -8 | N/A | -2 | N/A |
| 6/30/2017 | 9 | -8 | N/A | -2 | N/A |
| 3/31/2017 | 10 | -6 | N/A | 1 | N/A |
| 12/31/2016 | 9 | -5 | N/A | -7 | N/A |
| 9/30/2016 | 8 | -6 | N/A | -5 | N/A |
| 6/30/2016 | 7 | -6 | N/A | -4 | N/A |
| 3/31/2016 | 5 | -7 | N/A | -5 | N/A |
| 12/31/2015 | 4 | -6 | N/A | -4 | N/A |
| 12/31/2014 | 4 | -3 | N/A | -2 | N/A |
| 12/31/2013 | 4 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: CLBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CLBIO is expected to become profitable in the next 3 years.
Revenue vs Market: CLBIO's revenue (68.1% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: CLBIO's revenue (68.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLBIO's Return on Equity is forecast to be high in 3 years time (28.7%)